Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High – Time to Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $3.89 and last traded at $3.88, with a volume of 2500599 shares trading hands. The stock had previously closed at $3.59.

Analyst Ratings Changes

Several analysts have commented on XERS shares. HC Wainwright upped their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, Piper Sandler lowered shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Monday, November 11th.

Xeris Biopharma Stock Performance

The stock has a market capitalization of $591.85 million, a price-to-earnings ratio of -8.82 and a beta of 2.61. The stock’s 50 day moving average is $3.48 and its two-hundred day moving average is $3.14.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XERS. SG Americas Securities LLC boosted its stake in Xeris Biopharma by 188.5% in the 3rd quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock worth $172,000 after purchasing an additional 39,335 shares during the period. CWM LLC boosted its stake in Xeris Biopharma by 93.7% in the 3rd quarter. CWM LLC now owns 34,167 shares of the company’s stock worth $97,000 after purchasing an additional 16,530 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in Xeris Biopharma in the 3rd quarter worth $35,000. Goldstein Advisors LLC boosted its stake in Xeris Biopharma by 19.7% in the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after purchasing an additional 5,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Xeris Biopharma by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after purchasing an additional 11,239 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.